Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy involves the use of tocilizumab, a recombinant humanized monoclonal antibody, alongside standard-of-care (SOC) chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC) and estrogen-receptor (ER)-low breast cancer. Tocilizumab acts as an interleukin-6 (IL-6) receptor antagonist, blocking the pro-inflammatory signaling pathway that contributes to tumor growth, metastasis, and chemoresistance. The chemotherapy component, which may include agents like carboplatin, provides direct cytotoxic effects by damaging DNA or inhibiting cell division. This specific combination is being evaluated in a Phase II clinical trial led by Dr. Kathy Miller at Indiana University to determine if adding IL-6 inhibition to standard chemotherapy improves outcomes, particularly in Black and non-Black patient populations.
- Brand names
- Actemra
- Other names
- SOC Chemotherapy + Tocilizumabchemotherapy + tocilizumab
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on tocilizumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab + chemotherapy.